[Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers].
The authors evaluated the impact of a chronotherapy with 5-FU, folinic acid and carboplatine (chronomodulated infusions by ambulatory pumps; 5/21 days) for the management of oesophagus (52 cases) and gastric (56 cases) cancer patients. The overall tolerance of treatment was gauged excellent (grade 3-4; % patients: mucitis: 11-23%; leucopenia 6-19%; thrombopenia 18-50%; almost no digestive disturbances nor alopecia). Also tumor outcome was considered interesting with major responses rate in 61% (gastric) to 79% (oesophagus) of patients. The median survival of oesophageal cancer was limited to 9.2 months; the one of disseminated gastric cancer was 12.7 months but 72% of curatively resected patients were alive at 5+ years.
Focan
C
C
Département de médecine interne, oncologie, CHC, clinique Saint-Joseph, rue de Hesbaye 75, B-4000 Liège, Belgique. christian.focan@CHC.be
Kreutz
F
F
Longrée
L
L
Graas
M-P
MP
Moeneclaey
N
N
Demolin
G
G
Focan-Henrard
D
D
D000368:Aged; D000369:Aged, 80 and over; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D019454:Chronotherapy / Q000379:methods*; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology*; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D016190:Carboplatin; D002955:Leucovorin